Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor

Inclusion Criteria: * Age \> 18 years old * CAD patients (stable CAD, NSTE-ACS, or STEMI) undergoing PCI and treated with cangrelor per standard of care. * Treated with aspirin prior to the PCI procedure per standard of care Exclusion Criteria: * Treatment with an oral P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) within past 10 days * Treatment with oral anticoagulation (vitamin K antagonist, dabigatran, apixaban, rivaroxiban) within past 3 days * Treatment with a glycoprotein IIb/IIIa inhibitor during PCI * Fibrinolytics within 48 hours * Known hemoglobin\<10 gm/dL * Known platelet count \<80x106/mL * Active bleeding or hemodynamic instability * Known end stage renal disease on hemodialysis * Known severe hepatic dysfunction